• Skip to Page content
  • Skip to Management
  • Skip to Main menu
Charlottenburger Innovations-Centrum (CHIC), WISTA
  • WISTA
  • WISTA.Plan
  • WISTA.Service
  • WISTA direkt
  • Search
    • de
    • en
  • Charlottenburger Innovations-Centrum (CHIC), WISTA
  • Innovation Center
    • Benefits & Team
    • Services
    • Network & Partners
  • Rental Offers
    • Offices
    • Meeting Spaces
    • ST3AM Coworking
  • News / Events
    • Overview
    • CHIC on LinkedIn
  • Company Directory
  • Contact & Location
  • WISTA
  • WISTA.Plan
  • WISTA.Service
WISTA direkt
  • Home Innovation Center
  • News / Events

News / Events

  • Overview
  • CHIC on LinkedIn
  • Home Innovation Center
  • News / Events
14. July 2020

New substance library to accelerate the search for active compounds

Substance library of the HZB-MX team is available worldwide for the development of drugs, also in the search for active substances against SARS-CoV-2

fragment-screening workflow © HZB
The fragment libraries, which the MX team has assembled together with a group from the University of Marburg, are also available to users at BESSY II. The diagram shows the fragment-screening workflow. © HZB

In order to accelerate the systematic development of drugs, the MX team at the Helmholtz-Zentrum Berlin (HZB) and the Drug Design Group at the University of Marburg have established a new substance library. It consists of 1103 organic molecules that could be used as building blocks for new drugs. The MX team has now validated this library in collaboration with the FragMAX group at MAX IV. The substance library of the HZB is available for research worldwide and also plays a role in the search for substances active against SARS-CoV-2.

For drugs to be effective, they usually have to dock to proteins in the organism. Like a key in a lock, part of the drug molecule must fit into recesses or cavities of the target protein. For several years now, the team of the Macromolecular Crystallography Department (MX) at HZB headed by Dr. Manfred Weiss together with the Drug Design Group headed by Prof. Gerhard Klebe (University of Marburg) has therefore been working on building up what are known as fragment libraries. These consist of small organic molecules (fragments) with which the functionally important cavities on the surface of proteins can be probed and mapped. Protein crystals are saturated with the fragments and then analysed using powerful X-ray light. This allows three-dimensional structural information to be obtained at levels of atomic resolution. Among other things, it is possible to find out how well a specific molecule fragment docks to the target protein. The development of these substance libraries took place as part of the joint Frag4Lead research project and was funded by the German Federal Ministry of Education and Research (BMBF).

The MX team (MX stands for Macromolecular Crystallography) has now published the design of a chemically diverse fragment library called the “F2X-Universal“ library, which consists of 1,103 compounds. A representative selection of 96 compounds has been extracted from this library, which is referred to as the F2X Entry Screen. In the course of publishing the library, this selection has now been successfully tested and validated by the MX team of the HZB at the MAX IV X-ray source in Lund, Sweden and at BESSY II.

In the study, the HZB and MAX IV teams verified the efficiency of the F2X Entry library by screening endothiapepsin and the Aar2/RnaseH protein complex as the target enzymes. In the next step, the MX team will use the entire universal library.

“For the current study, the fragment screening experts at HZB - BESSY II worked very closely with the FragMAX project team at MAX IV“, said Dr. Uwe Müller from the MX team at HZB who helped to set up the three MX beamlines at BESSY II as well as the BioMAX beamline at MAX IV. “This enabled both partners to further develop their own technology platforms and use them for imaging the functional surfaces of different proteins. This will be an excellent basis for future collaboration between MAX IV and HZB.“

Publication:

Structure (2020): F2X-Universal and F2X-Entry: Structurally Diverse Compound Libraries for Crystallographic Fragment Screening. Jan Wollenhaupt, Alexander Metz, Tatjana Barthel, Gustavo Lima, Andreas Heine, Uwe Mueller, Gerhard Klebe, Manfred S. Weiss
DOI: 10.1016/j.str.2020.04.019
 

Contact:

Helmholtz-Zentrum Berlin für Materialien und Energie
Research Group Macromolecular Crystallography

Dr. Jan Wollenhaupt
Phone: +49 30 8062-13483
Email: jan.wollenhaupt(at)helmholtz-berlin.de

Dr. Manfred Weiss
Phone: +49 30 8062-13149
Email: manfred.weiss(at)helmholtz-berlin.de

Analytics Research Corona Biotechnology / Environment Photonics / Optics

Related News

3D model of a protein

5000th protein structure at BESSY II – Starting point for a COVID drug

HZB team has identified 21 molecules as candidates for the development of antiviral drugs
Portrait Andrea Thorn

New department at HZB: ‘AI and Biomolecular Structures’

Andrea Thorn, head of the department, brings many years of experience in AI-based tools for structural biology
MX team BESSY II © HZB

HZB coordinates European collaboration to develop active agents against Corona

The MX team at BESSY II specialises in analysing protein structures
Protein crystals analysis in the MX laboratory at BESSY II © C. Feiler/HZB

Corona research: Consortium of Berlin research and industry seeks active ingredients

The HZB is making all existing infrastructures available to the joint project
Schematic representation of the coronavirus protease © Helena Tabermann/HZB

Corona research at BESSY II

Two days of measuring operation to find the right key
Schematic representation of the coronavirus protease © HZB

Coronavirus: BESSY II data accelerate drug development

Scientists have decoded the three-dimensional architecture of the main protease of SARS-CoV-2
PILATUS detector © HZB

New detector accelerates protein crystallography

MX Beamline at BESSY II works about 2 to 3 times faster than before

Cancer research at BESSY II

Binding Mechanisms of Therapeutic Substances Deciphered

Share this page

  • © WISTA Management GmbH
  • Legal Notice
  • Privacy Policy
  • Social Media
  • Contact
Zukunftsort Charlottenburg Logo